Welcome to our dedicated page for NewAmsterdam Pha SEC filings (Ticker: namsw), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on NewAmsterdam Pha's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into NewAmsterdam Pha's regulatory disclosures and financial reporting.
NewAmsterdam Pharma Co N.V. received an updated Schedule 13G/A (Amendment No. 3) from investment entities affiliated with Viking Global, disclosing their passive ownership in the company’s ordinary shares.
The Viking-related entities collectively report beneficial ownership of 4,203,567 ordinary shares, representing 3.7% of the outstanding class, based on 113,390,804 ordinary shares outstanding as of October 31, 2025. The shares are held through two main limited partnerships, which directly own 2,817,205 and 1,386,362 ordinary shares, respectively. Key individuals O. Andreas Halvorsen, David C. Ott and Rose S. Shabet are reported as having shared voting and dispositive power over these holdings through their roles in Viking’s general partner and parent entities.
The filing states that the securities were not acquired and are not held for the purpose of changing or influencing control of NewAmsterdam Pharma, indicating a passive investment stance under the 13G framework.
FMR LLC has filed a Schedule 13G reporting beneficial ownership of 6,412,984 shares of Pharma Company NV common stock, representing 5.7% of the class as of the event date. FMR has sole voting power over 6,403,075 shares and sole dispositive power over 6,412,984 shares.
Abigail P. Johnson is also reported as a beneficial owner with sole dispositive power over the same 6,412,984 shares and no voting power. The filing states the shares were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of Pharma Company NV.
NewAmsterdam Pharma Co N.V.’s Chief Accounting Officer Louise Frederika Kooij reported option exercises and share sales in late January 2026. On January 27, 2026, she exercised 39,816 options at an exercise price of $10.90 per ordinary share and acquired the same number of ordinary shares.
That same day she sold 39,816 ordinary shares at a weighted average price of $32.62 per share, leaving 24,353 ordinary shares directly owned afterward. On January 28, 2026, she exercised another 32,612 options at $10.90 per share and acquired 32,612 ordinary shares, then sold 32,612 ordinary shares at a weighted average price of $31.80 per share.
After these transactions, she directly held 24,353 ordinary shares and 73,134 options (options with a $10.90 exercise price and an expiration date of January 1, 2033). The filing notes that the sale prices are weighted averages across multiple trades within the stated price ranges.
NewAmsterdam Pharma Co N.V.’s Chief Accounting Officer, Louise Frederika Kooij, reported multiple option exercises and share sales in January 2026. On January 23, 2026, she exercised options for 38,172 ordinary shares at an exercise price of
On January 26, 2026, she exercised additional options for 34,400 ordinary shares at
NewAmsterdam Pharma Co N.V.’s Chief Financial Officer, Mayur Ian Somaiya, reported stock option exercises and related share sales. On January 20 and 21, 2026, he exercised options to acquire 60,216 and 39,784 ordinary shares at an exercise price of
After these transactions, Somaiya directly held 58,382 ordinary shares and 662,814 option-based derivative securities. The filing states that at least one sale transaction was carried out under a Rule 10b5-1 trading plan, and notes that the underlying option was granted on
NAMS reported that an affiliated holder has filed a Rule 144 notice to sell 200,000 ordinary shares through J.P. Morgan Securities LLC on or about 01/20/2026 on Nasdaq. The planned sale has an indicated aggregate market value of $6,330,000. The seller acquired the 200,000 shares from the issuer on the same date via a stock option exercise paid in cash. The filing also lists 113,390,804 ordinary shares outstanding for the issuer, providing context for the size of this planned transaction.
James N. Topper, a director of NewAmsterdam Pharma Co N.V. (ticker: NAMSW), reported a purchase on Form 4. The filing shows a transaction on 09/15/2025 acquiring 660 ordinary shares at a weighted average price of $23.6953. The filing lists two holdings following the reported transaction: 3,028,524 shares held indirectly by Frazier Life Sciences X, L.P. and 3,801,000 shares held indirectly by Frazier Lifesciences Sponsor LLC. Footnotes state the reported price is a weighted average from multiple purchases priced between $23.46 and $23.75. The Form 4 was signed by an attorney-in-fact on behalf of Mr. Topper on 09/17/2025.
Louise Frederika Kooij, Chief Accounting Officer and director of NewAmsterdam Pharma Co. N.V. (NAMS), reported multiple transactions on 09/09/2025. The filing shows an acquisition of 150,000 ordinary shares at $10.00 and contemporaneous dispositions of 53,104 shares at a weighted average $25.31 and 96,896 shares at a weighted average $26.11, reflecting sales executed across prices in the ranges disclosed. The filing also reports derivative activity: an option with a $10 exercise price (granted 11/22/2022) covering 150,000 underlying shares that vest monthly over four years beginning 12/01/2022. After the reported transactions the schedules list beneficial ownership figures shown in the form, and the report is signed on 09/10/2025.
James N. Topper, a director, reported purchases of NewAmsterdam Pharma Co N.V. ordinary shares on 09/08/2025. The Form 4 shows 1,260 shares acquired at a weighted average price of $24.99 (prices ranged from $24.86 to $25.00). Following the transaction, the filing reports 3,027,864 shares held indirectly by Frazier Life Sciences X, L.P. and 3,801,000 shares held indirectly by Frazier Lifesciences Sponsor LLC. The securities are held indirectly through a partnership and sponsor entities for which the reporting person is a managing member; the filing disclaims direct beneficial ownership except for pecuniary interest. The form is signed by an attorney-in-fact on behalf of Mr. Topper dated 09/10/2025.
NewAmsterdam Pharma Company N.V. insider activity is reported under Rule 144 for ordinary shares. The filer indicates an intended sale of 150,000 ordinary shares through J.P. Morgan Securities LLC with an aggregate market value of $3,780,000, and lists the approximate sale date as 09/09/2025 on NASDAQ. The shares were acquired on 11/22/2022 via an equity compensation exercise-and-sell transaction from the issuer, and payment is listed as cash. The filing also discloses two prior share sales by the same person in the past three months totaling 26,342 shares for gross proceeds of $658,999.39.